12:00 AM
Feb 28, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

RA-INF-Dx blood test update

TcLand began the open-label, European PRINT trial to evaluate the performance of its RA-INF-Dx blood test in 200 RA patients who are unlikely to show an initial response to infliximab and...

Read the full 135 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >